Genmab

Founded in 1999, Genmab operates at the forefront of biotechnology, specialising in the creation and development of innovative antibody therapeutics for the treatment of cancer. With headquarters in Copenhagen, Denmark, Genmab's mission is to improve the lives of patients by leveraging cutting-edge science to create differentiated antibody therapeutics that address high unmet medical needs.

Genmab is renowned for its unique approach to antibody development, harnessing its expertise in oncology to design, develop, and deliver next-generation cancer therapies. The company's scientific capabilities are supported by a robust research and development pipeline, which focuses on the discovery and clinical testing of its proprietary antibody products.

Under the leadership of CEO Jan van de Winkel, Genmab continues to thrive as a leader in the biopharmaceutical industry, driven by a commitment to innovation and collaboration. The company's dedication to advancing science for the benefit of patients underpins its strategic partnerships and alliances, ensuring Genmab remains at the cutting edge of therapeutic development.